Proteinuria in IgAN: The Signal, The Target, and the Treatment Goal
Jonathan Barratt, MD, PhD
An De Vriese, MD, PhD
Translating Evidence into IgAN Care
Jörg Latus, MD
The Future of IgAN Care
Chee Kay Cheung, MBChB, MRCP, PhD
Engaging Patients With Heart Failure and Chronic Hyperkalemia: Shared Decision-Making to Support Guideline-Directed Medical Therapy
Gianluigi Savarese, MD, PhD, FESC, FHFA
CKD-aP Uncovered Prevalence & Pathophysiology
Steven Fishbane, MD
Nancy Helou, PhD
Itching for Answers: Holistic CKD-aP Care
Federico Alberici, MD, PhD
Anastasia Liossatou, PhD, RN
Spotlight on Assessment: Tools That Capture CKD-aP
Frontline Champions: Nurses as Drivers of Symptom-Based CKD-aP Care
When Itching Hurts: Quality of Life Disruption in CKD-aP
Translating the Latest KDIGO Guidelines Into Practice: IV Iron Therapy in Patients With Non–Dialysis-Dependent CKD
Patrick Rossignol, MD, PhD
Julio Núñez, MD, PhD
Vous prescrivez uniquement des antihistaminiques pour traiter les patients atteints de Pa-MRC ? Il est temps de revoir votre approche !
Antoine Lanot, MD, PhD
Gil Yosipovitch, MD
Stuck on Antihistamines for Managing Patients With CKD-aP? Time to Reconsider!
Inside the IgAN Clinic: Shared Decision-Making Into Practice
Case-Based Approach: Managing Hyperkalemia in Patients With CKD and Heart Failure
Ellie Kelepouris, MD, FACP, FAHA
Nihar R. Desai, MD, MPH
Targeting CKD-aP at the Source: Key Mechanisms and Treatments
Maurizio Gallieni, MD
Elevating CKD-aP Care: New Frontier
James Burton, DM, FRCP
Lucio Manenti, MD, PhD
Loading...
NEW FEATURES:
Tell us what you think by using our Feedback button
We're glad to see you're enjoying Global Kidney Academy… but how about a more personalized experience?
Press cancel to remain on Global Kidney Academy. Press the link below or the continue button to keep going.